3-Methyladenine (3-MA)

For research use only.

Catalog No.S2767 Synonyms: NSC 66389

551 publications

3-Methyladenine (3-MA) Chemical Structure

CAS No. 5142-23-4

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's 3-Methyladenine (3-MA) has been cited by 551 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)		 PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K562 MWXGeY5kfGmxbjDBd5NigQ>? MUmxNI1O NHTDdIkycA>? M2rINIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NIHPZYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi2OFA{Pyd-MkG4OlQxOzd:L3G+
Jurkat Mny3SpVv[3Srb36gRZN{[Xl? NF\5cVUyOG2P MXSxbC=> MlGz[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MnXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NkSwN|coRjJzOE[0NFM4RC:jPh?=
HeLa  NU\qNpB2S3m2b4TvfIlkcXS7IFHzd4F6 MnHRNo1O NV7ISJhCOjSq M{nsc4lvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> M{Die|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEe1N|g2Lz5{MUi3OVM5PTxxYU6=
PC12/TetOn Mn;4SpVv[3Srb36gRZN{[Xl? NV\SeHZvOC5zL{HtUS=> MnTPNVhp MWns[YFleyC2bzFOtU1{gW5qV2SpJIFk[3WvdXzheIlwdixidH;4bYNqfHluIHHu[EBwdGmpb33ldkBnd3KvYYTpc47DqA>? NGj2dJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmwOlY2QSd-MkG5NFY3PTl:L3G+
RMPI8226  M2\CNmZ2dmO2aX;uJGF{e2G7 MlX2OY1O MknWNYg> Mm[5d5VxeHKnc4Pld{B1cGVibHX2[Ywhd2ZiYYX0c5Bp[We7IIXu[IVzKG63dILp[Y51KGSncHzleIlwdg>? NYezSZRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NVU3OjBpPkKxPVE2PjJyPD;hQi=>
MCF-7 NYj2T3N[TnWwY4Tpc44hSXO|YYm= NUPIRWlFOTCvTR?= M3[4V|Q5cA>? NF;Yd3VjdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>? NInsSpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmzNVk{Pyd-MkG5N|E6Ozd:L3G+
HBx  MVrBdI9xfG:|aYOgRZN{[Xl? NGnLSI4yOG2P M3;lSVQ5cA>? MkfzSG1UVw>? M{D6XIlv[3KnYYPld{Bk\WyuIHTlZZRp MmrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMkCwO|goRjJ{MEKwNFc5RC:jPh?=
Marc-145 MXrGeY5kfGmxbjDBd5NigQ>? MW[1cW0> M{mydFEzNzJ2L{O2bC=> MVPy[YR2[2W|IITo[UBRWlKVVjD0bZRmenNiYX7kJJRp\SCycn;0[YlvKGW6cILld5Nqd25? NYfyXHo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNVk6ODBpPkKyNVE6QTByPD;hQi=>
U937 NGrzZ5pHfW6ldHnvckBCe3OjeR?= NWmwcZI3Om2P M1m3XlEzcA>? NUnZfod7\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= NGLpVWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1OVE2OCd-MkKxOVUyPTB:L3G+
BGC-823 NYPFSlJ3TnWwY4Tpc44hSXO|YYm= NU\OSZVrPW2P NFzNXZEzcA>? NWWz[WhqcW6qaXLpeJMhfGinIILheIUhd2ZiYYX0c5Bp[WerYzDj[Yxtew>? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN{MkG1Nkc,OjJ|MkKxOVI9N2F-
A549 M2DZR2Z2dmO2aX;uJGF{e2G7 NVvicZlpOC5zbV2= NFvuWZUzPGh? MmT3d5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR4Nkm2NEc,OjJ2Nk[5OlA9N2F-
pDCs MXHGeY5kfGmxbjDBd5NigQ>? MWOxNI1O NU\vV5NQOC53aB?= NET3PYfDqHKnZIXj[ZMhfGinIHnu[JVkfGmxbjDv[kBKTk5vzsGgZpkhe3OUTlG0NC=> MlfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|OU[1PVkoRjJ{M{m2OVk6RC:jPh?=
HeLa  NFrqdGxCeG:ydH;zbZMhSXO|YYm= NXvEZmNuPW2P Mo\PNlRp NHPsT3FqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JINmdGxiZHXheIg> NGnXRlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0OVEzQCd-MkK1OFUyOjh:L3G+
U251  M2H6OWFxd3C2b4Ppd{BCe3OjeR?= MofIOY1O NV7TWXNVOjSq MkeybY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV5OUe4PEc,OjJ3N{m3PFg9N2F-
MCF-7  NVPhR3dRSXCxcITvd4l{KEG|c3H5 MXmwMlFuVQ>? MnfPOog> MYXlcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?= M3TJXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{WxPVg6Lz5{Mke1NVk5QTxxYU6=
PC-3  NVLIRoJzSXCxcITvd4l{KEG|c3H5 MkT6No1O MXuybC=> MkG5bY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? NFX0S3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0OVU5OCd-MkK3OFU2QDB:L3G+
HCT116 NES2enJCeG:ydH;zbZMhSXO|YYm= M3zTflVuVQ>? NUf3bVk4OjSq M2nObGROW09? MnnF[Y5p[W6lZYOgZZBq\2WwaX6tbY5lfWOnZDDj[YxtKGSnYYTo NXTyVVQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlY2OjJpPkK0OlI3PTJ{PD;hQi=>
U2OS NWH2[W1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fa[|ExdU1? Mo\xNlRp NHnLWo5qdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUBFd3h? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|OUCxN{c,OjR4M{mwNVM9N2F-
A2780cp MUjBdI9xfG:|aYOgRZN{[Xl? NUDUN4d5Oi53bV2= NXvHe5hEOWh? MXHk[GgzVw>? NXPqWYhq\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NVq0Z2NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVc6PDZpPkK0PFE4QTR4PD;hQi=>
HepG2 MYHGeY5kfGmxbjDBd5NigQ>? Mm\LOY1O MYm0bC=> NVnxUoZwcW6lcnXhd4V{KGOnbHz1cIFzKGyndnXsd{Bw\iCKTNMg NH3qVZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEexN|U5Pyd-MkS3NVM2QDd:L3G+
Microglia  NUjh[W9RSXCxcITvd4l{KEG|c3H5 M{eye|VuVQ>? NGS3UoszPGh? Mmq5[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo NEO4[3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPFYxOSd-MkS4NVg3ODF:L3G+
MDA-MB 231 MmDKRZBweHSxc3nzJGF{e2G7 NWj6TJdmPW2P MorsNE42cA>? M4HIOI1w\HWuYYTld{BVd2OxbXnuxs7DqGmwZIXj[YQh[XCxcITvd4l{ NHvL[Vc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNFc5OSd-MkS4N|A4QDF:L3G+
PANC-1  NYjtPYpXSXCxcITvd4l{KEG|c3H5 MXuxcW0> NYrrZoJyPDiq MULEUXNQ NH\IS4NmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh2MkG1PEc,OjR6NEKxOVg9N2F-
MDA-MB-231 M37RO2Z2dmO2aX;uJGF{e2G7 M2H2S|JuVQ>? NVX0RnZ3PDiq NEPrOIxxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? MkXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{C2O|YoRjJ2OUewOlc3RC:jPh?=
MDA-MB-231 MoDGSpVv[3Srb36gRZN{[Xl? MmT1No1O M3\yPVI1cA>? MV3pcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{C2O|YoRjJ2OUewOlc3RC:jPh?=
MCF-7  MWDGeY5kfGmxbjDBd5NigQ>? MYGycW0> NF;WbXk1QGh? NYjD[IJZeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq NH;DZXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3NFY4Pid-MkS5O|A3PzZ:L3G+
MCF-7  M4P1b2Z2dmO2aX;uJGF{e2G7 MVeycW0> NHHz[48zPGh? M4LzeYlvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= M3zNZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUewOlc3Lz5{NEm3NFY4PjxxYU6=
HepG2 M2WwT2Fxd3C2b4Ppd{BCe3OjeR?= MYKzcW0> MYq1bC=> NWTxT|BLemWmdXPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHFFew>? NX:zZndyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|Y2QTVpPkKyPFM3PTl3PD;hQi=>
HeLa MY\BdI9xfG:|aYOgRZN{[Xl? MV2xNI1O NHjFdlAzcA>? MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliY3:teJJm[XSvZX70JJdqfGhiUFXJ NHKzSo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CwNFE{PSd-MkOwNFAyOzV:L3G+
SK-HEP-1 M3\pZmFxd3C2b4Ppd{BCe3OjeR?= NV;QRVhwOTCvTR?= NGT4c4kycA>? M2O1WpBzd3SnY4TzJIFo[Wmwc4SgZZV1d3CqYXf5JIFv\CCrbnT1Z4V{KGGyb4D0c5NqeyCrbjDieYZidGmwLYTy[YF1\WRiY3XscJM> NYDY[5dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVg3PDlpPkKyPFU5PjR7PD;hQi=>
MDA-MB231 Mn3aSpVv[3Srb36gRZN{[Xl? MkDTOY1O MWWxbC=> NU\qO25TcW6lcnXhd4V{KHKnc4\ldoF1em:uLX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? M4D0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEi4PFUxLz5{M{C4PFg2ODxxYU6=
PaCa44 NGHEOlRCeG:ydH;zbZMhSXO|YYm= Mm\1Nk42dU1? M1rKelFp M4TlOJJm\HWlZYRCpIdmdmmyaX6tcYVlcWG2ZXSgZZBweHSxc3nz MmXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMkSxNVIoRjJ|MUK0NVEzRC:jPh?=
T-47D NIfRT4lHfW6ldHnvckBCe3OjeR?= NFXyWooyOG2P NELkW4MzcA>? NX;keIJtcW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMECyOkc,OjN|MECwNlY9N2F-
GTL-16  MVfBdI9xfG:|aYOgRZN{[Xl? NULDdpV{PW2P NYW0dppsOjSq Mkf5doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjczDjc41x[XKnZDD0c{Bk\WyuczD0doVifGWmIIfpeIghVUWWIHnubIljcXSxcoO= M{HiT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{GzOFkxLz5{M{OxN|Q6ODxxYU6=
U251MG  NYXiXVh7TnWwY4Tpc44hSXO|YYm= MlLZN41O M4PRVlFp NFTKdFF{fXCycnXzd4V{KEyFMz3JTUBxem:2ZXnuJIV5eHKnc4Ppc44> NI\LUY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OzPFYyQCd-MkOzN|g3OTh:L3G+
T24 NH3lbIVHfW6ldHnvckBCe3OjeR?= NWP1XIRPOTCvTR?= M37mWVFp M1zsWZJm\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIFzDN{Bi\nSncjDiZYlk[WyrbjD0doVifG2nboS= M4\FbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0NFgxLz5{M{O1OFA5ODxxYU6=
HUVECs NWLjeoxnTnWwY4Tpc44hSXO|YYm= MmL5N41O M37aT|I1cA>? NInkdXFjdG:la4OgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIILld5ZmemG2cn;sJIJ6KGmwaHnibZRqdmdiYYX0c5Bp[We7 NVTPfXZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVg6OjhpPkKzN|U5QTJ6PD;hQi=>
MCF-7  M4DPcWZ2dmO2aX;uJGF{e2G7 MVe1cW0> MkK0NlRp NYnOPVVvcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? M2TOfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{m1Olc6Lz5{M{O5OVY4QTxxYU6=
Hela  NVf0ZZpsTnWwY4Tpc44hSXO|YYm= M3T2clVuVQ>? MlK5NlRp NInnUWxqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 NGnFNoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OVY4QSd-MkOzPVU3Pzl:L3G+
OR6 M4XjO2Z2dmO2aX;uJGF{e2G7 NInLeGkyOG2P MUe3Nog> MU\zeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{ NYT0e29tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVU5PzVpPkKzN|k2QDd3PD;hQi=>
HT-29  MUnGeY5kfGmxbjDBd5NigQ>? NI\CU4IydU1? NGHBOWY1QC97Nni= MkjDbY5pcWKrdIOgRW1RUyCrbnT1Z4V{KGG3dH;wbIFocWNiY3XscEBl\WG2aB?= NYPZPFBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NFgzPzJpPkKzOVA5Ojd{PD;hQi=>
SH-SY5Y MorxR5l1d3SxeHnjbZR6KEG|c3H5 NWL0dpFYPW2P NUHB[WNiOjSq NGjiS4tqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV{NUK2OUc,OjN3MkWyOlU9N2F-
Saos-2  MVzBdI9xfG:|aYOgRZN{[Xl? M2rv[VFuVQ>? MUK5Oog> M4PEW4lv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY NY\jRY1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlMyPzFpPkKzOVY{OTdzPD;hQi=>
1321N1 NEjrd49EgXSxdH;4bYNqfHliQYPzZZk> MX61cW0> MXuyOIg> MnjGdJJwfGWldIOgZ4VtdCCjZ3HpcpN1KFCFTj3pcoR2[2WmIITvfIlkcXS7 MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV{NUK2OUc,OjN3MkWyOlU9N2F-
A2780 Mo\jRZBweHSxc3nzJGF{e2G7 M3T6eVVuVQ>? MmLVNlRp MWfjc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? NIPSOWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5NlI5OSd-MkO1PVIzQDF:L3G+
OV2008 NFHNU4RCeG:ydH;zbZMhSXO|YYm= MnvhOY1O NYLUXXBxOjSq MoGzZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? NIPFdWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5NlI5OSd-MkO1PVIzQDF:L3G+
PC12  MWLGeY5kfGmxbjDBd5NigQ>? NGrB[2oyOG2P Mm\sNlRp MWT3ZZRmeg>? NI\rPGjDqGmwaHnibZR{KGOqeX3veJJ6eHOrbj3sbYtmKHC{b4TlZZNwdWGuIHHjeIl3cXS7Lh?= M{L0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkCzPVc6Lz5{M{[wN|k4QTxxYU6=
SH-SY5Y M{HsdmFxd3C2b4Ppd{BCe3OjeR?= M1\KV|VuVQ>? Mk\zNYg> NWXyN|E3[WKxbHnzbIV{KGOnbHHzeJJwdCCwZYXyc5Bzd3SnY4TpeoUh\W[oZXP0 NFjab489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xPVM6PSd-MkO2NVk{QTV:L3G+
SH-SY5Y Ml7CSpVv[3Srb36gRZN{[Xl? NFvrSI8ydU1? NWr2SG54OjSq NXfLUXdkcW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRQS1B? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2M{G0PEc,OjN5NEOxOFg9N2F-
HepG2 MVLGeY5kfGmxbjDBd5NigQ>? NWTtRYZnOTCvTR?= NV\oe|Q3OjSq NEHNR4dqdmirYnn0d{B{cVSLR1HSMUBidmRiSFLTV{1qdmS3Y3XkJIF2fG:yaHHnfS=> NFrSSZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ixO|A1OCd-MkO4NVcxPDB:L3G+
HeLa Mk\tSpVv[3Srb36gRZN{[Xl? NXvzS2dvOTCvTR?= MnrlNog> MkDUd5VxeHKnc4Pld{BNSzNiSVmg[ZhxemW|c3nzc44> NEez[5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2OFc{QCd-MkO4OlQ4Ozh:L3G+
HONE-1  M4K5WWZ2dmO2aX;uJGF{e2G7 NWjXV5NjPW2P NHvWUXIycA>? MlL1doVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u NG\4dJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i5NlM2QCd-MkO4PVI{PTh:L3G+
MCF7 NXKxWZVFTnWwY4Tpc44hSXO|YYm= M33GelVuVQ>? MWqyOIg> NWDzVFJ5cW6lcnXhd4V{KEO3TzDpcoR2[2WmIHPlcIwh\GWjdHi= NHnjO|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlYzQSd-MkO5OlI3Ojl:L3G+
HO8910 MUnBdI9xfG:|aYOgRZN{[Xl? Mn3aNVBuVQ>? NUXBZ3RzOTKq M4mxb4VvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq NXO3dmJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PFM3OTBpPkKzPVg{PjFyPD;hQi=>
SMMC-7721 NWq3R5FJSXCxcITvd4l{KEG|c3H5 MlT4OY1O M4HCbVI1cA>? MojhZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz M3HzXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[2Olk{Lz5{NEC2OlY6OzxxYU6=
Hep3B MYXBdI9xfG:|aYOgRZN{[Xl? M4\YWlVuVQ>? NX\QXmJMOjSq MV7heJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= Mo\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNk[2PVMoRjJ2ME[2Olk{RC:jPh?=
H460 MWHGeY5kfGmxbjDBd5NigQ>? MmrwNVBuVQ>? M3\CTVRp Mmm5bY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> M3y0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUezNlA5Lz5{NEG3N|IxQDxxYU6=
A549 NV;He2hmTnWwY4Tpc44hSXO|YYm= NEnENVMyOG2P M1ju[VRp MWrpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBqenKjZHnheIlwdg>? NYXnZXM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFI4OzVpPkK0NVQzPzN3PD;hQi=>
H1299  MVTGeY5kfGmxbjDBd5NigQ>? M2Pje|ExdU1? MkTFOIg> MlfCbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NXHGO5d{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|MzODhpPkK0NVc{OjB6PD;hQi=>
WiDr MXrGeY5kfGmxbjDBd5NigQ>? M3XWXVExdU1? NYniOYxNOWh? M{XqNIlvcGmkaYTzJHBESkxvaX7keYNm\CCOQ{OgTWkh\XiycnXzd4lwdg>? NFTFVW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG5NFQ5QSd-MkSxPVA1QDl:L3G+
LoVo  M2\BXGFxd3C2b4Ppd{BCe3OjeR?= M1OwPFVuVQ>? MXW0PIg> Mn3H[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyMUixNkc,OjR{MEG4NVI9N2F-
HepG2 E47 Mm\FSpVv[3Srb36gRZN{[Xl? NEDGdYgzNjWvTR?= Mnv1OFhp MkC1bY5kemWjc3XzJJRp\SC2b4jpZ4l1gSCxZjDBRUwhSlORLDDhcoQhS0OuNB?= M2\uNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezO|M5Lz5{NEK3N|c{QDxxYU6=
RKO NFfvSYlHfW6ldHnvckBCe3OjeR?= M2TmTFJuVQ>? MmnsNYg> M{nT[WROW09? NIHqOYFmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUG3O|coRjJ2MkmxO|c4RC:jPh?=
Hep3B M2fVWWFxd3C2b4Ppd{BCe3OjeR?= M4PDNlJuVQ>? NGPOTG8yOmh? MULEUXNQ MXjpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= M2H2O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3N|AxLz5{NEK5O|MxODxxYU6=
ACHN-5968 MVrBdI9xfG:|aYOgRZN{[Xl? M3TST|VuVQ>? M3jpbVNp NYC5V5FU\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNyNU[wOEc,OjR|MEW2NFQ9N2F-
Huh7 M3f1XGFxd3C2b4Ppd{BCe3OjeR?= MWWycW0> MlHZNVJp NWm5fXdMTE2VTx?= MU\pcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUezNFAoRjJ2Mkm3N|AxRC:jPh?=
UOK257 NV3WUmdxSXCxcITvd4l{KEG|c3H5 M{TkTFVuVQ>? MmHVN4g> NXu5dnMx\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNyNU[wOEc,OjR|MEW2NFQ9N2F-
ECSCs  NHz1fFNCeG:ydH;zbZMhSXO|YYm= M{noWVExdU1? MYC0bC=> NXz5bItM\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDNzOUGwPUc,OjR|MUmxNFk9N2F-
MCF-7  NYG0RnpxTnWwY4Tpc44hSXO|YYm= M1niRlExdU1? NX7XTnNnOjSq NVPLTIwzcW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JINp\W2xdHjldoFxgSCmcoXndy=> NUDZW2t4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVU2PzhpPkK0N|E2PTd6PD;hQi=>
SGC-7901  Mk[5RZBweHSxc3nzJGF{e2G7 NWHTTmNwOm2P NX3JN|N4OWh? MoXabY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? NFX4Nnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyNVM1OCd-MkSzNlE{PDB:L3G+
SMMC-7721 Mo\lRZBweHSxc3nzJGF{e2G7 NXLjOmZFOm2P NV7xTG1NOWh? M3zFRolv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{MUO0NEc,OjR|MkGzOFA9N2F-
T24 MV\BdI9xfG:|aYOgRZN{[Xl? MXG1cW0> M1rHbFEvPWh? MmnvdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN2OUG3Okc,OjR|NEmxO|Y9N2F-
NTUB1 NXzQVZV3SXCxcITvd4l{KEG|c3H5 Mn;POY1O M4DwbFEvPWh? M37mbpBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? M{exSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{S5NVc3Lz5{NEO0PVE4PjxxYU6=
MG-63 NXvSRXpMSXCxcITvd4l{KEG|c3H5 Ml3QNVBuVQ>? MkS4NVJp MVXlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUizNFEoRjJ2M{W4N|AyRC:jPh?=
MG-63 NF7mdGFCeG:ydH;zbZMhSXO|YYm= MoTONE42NzGvTR?= NW\U[JJCOzKq NFHYTlRmdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz NXr5XWJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVg{PDJpPkK0N|U5OzR{PD;hQi=>
MG-63 MlvuSpVv[3Srb36gRZN{[Xl? NV6xenMxOC53L{HtUS=> M4m2V|Q5cA>? NWnv[np6cW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MlfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUizOFIoRjJ2M{W4N|QzRC:jPh?=
U2OS  NHfVcplHfW6ldHnvckBCe3OjeR?= M33YVVAvPS9zbV2= M3e1bVQ5cA>? MWHpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUizOFIoRjJ2M{W4N|QzRC:jPh?=
HGC-27 NG\tUolHfW6ldHnvckBCe3OjeR?= M4DPW|ExdU1? MmX3NYg> NFuzTVJqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhdG:|czDifUBTSURyMEGgc5IhVUtvMkKwOi=> NVz5dmVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVY{PDlpPkK0OFE3OzR7PD;hQi=>
HCT116  M1\nc2Fxd3C2b4Ppd{BCe3OjeR?= NInZ[Is2dU1? NHjGdHIzPGh? M1zBdYVvcGGwY3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDhdIlo\W6rbh?= M2TqXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkK2OVIzLz5{NE[yOlUzOjxxYU6=
A549 M{C0SGFxd3C2b4Ppd{BCe3OjeR?= MV2xNI1O MkH6OFhp M1XNOoFk[2WuZYLheIV{KHSqZTDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBRXFh? NILLdFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yOlczOid-MkS2NlY4OjJ:L3G+
Saos-2 NWLSOY9VSXCxcITvd4l{KEG|c3H5 MkPhNVBuVQ>? NGn2[oozPGh? M3vZVYlvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|OUCxN{c,OjR4M{mwNVM9N2F-
U2OS NWjzfGZTSXCxcITvd4l{KEG|c3H5 MlrwNVBuVQ>? M4rpZ|I1cA>? MXLpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> NVrmenJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N|kxOTNpPkK0OlM6ODF|PD;hQi=>
HepG2 NV3uSoM6TnWwY4Tpc44hSXO|YYm= M1;JTFVuVQ>? NUHHPFRIPGh? MWHpcoNz\WG|ZYOgTGwhemWuZXHz[S=> NHPpfGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEexN|U5Pyd-MkS3NVM2QDd:L3G+
A549 MUjBdI9xfG:|aYOgRZN{[Xl? M{fsZ|VuVQ>? MVS0PIg> M1XkOIRm[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuIHTlZZRpKGGwZDDlfJBz\XO|aX;uJIxmfmWuczDv[kBk[XOyYYPlMVMtKEKnY3zpck0yKGGwZDDMR|MuUUl? NIjCbJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOlMxOyd-MkS3NFY{ODN:L3G+
A2780cp NWLzcmlKSXCxcITvd4l{KEG|c3H5 M2LvfVIvPW2P NIXmS2QycA>? M2PDR4RlUDKR M3y1S4VvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NHHBSGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixO|k1Pid-MkS4NVc6PDZ:L3G+
Microglia  MW\BdI9xfG:|aYOgRZN{[Xl? M3H3[lVuVQ>? NUfqPJJ5OjSq Mn;G[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo MmGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUi2NFEoRjJ2OEG4OlAyRC:jPh?=
HT-29  NFGwe4VCeG:ydH;zbZMhSXO|YYm= NF3YR5QydU1? MnfvOFhp M{DDbmROW09? MXLlcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NEnoeWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi0NlE2QCd-MkS4OFIyPTh:L3G+
MDR NEjpT|JCeG:ydH;zbZMhSXO|YYm= MlPqNVBuVQ>? MnH2Oog> NVH6S3dFe3S{ZX7neIhmdnNidHjlJJBwf2W{IH;mJIFvfGmlYX7j[ZIh\HK3Z4O= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzOUewNUc,OjVyMUm3NFE9N2F-
H157 MUPGeY5kfGmxbjDBd5NigQ>? NV60emtHPW2P NVnKTZJIOmh? NGL0OJZ{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> MlvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OEW2NlgoRjJ3Mki1OlI5RC:jPh?=
A549  NILt[FFHfW6ldHnvckBCe3OjeR?= NXK5O3NmPW2P M4[3Z|Jp MWPzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= NEXYXos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK4OVYzQCd-MkWyPFU3Ojh:L3G+
A2780cp  NFrUelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ZeYEydU1? NXXtRYVbOWh? NVnnW5VCcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN{Mk[5OEc,OjV|MkK2PVQ9N2F-
NBL-W-S  NIHzcWxCeG:ydH;zbZMhSXO|YYm= M4DBN|FuVQ>? NFvmO5g3cA>? NWjlS5EzcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhT0GQVD22NS=> Mo\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MkOyNlIoRjJ3M{KzNlIzRC:jPh?=
NBL-W-S  NFu3R4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rhcVFuVQ>? M1[2dFZp NXTRcYh7\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=> NFz1S2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOyN|IzOid-MkWzNlMzOjJ:L3G+
A549  MVLBdI9xfG:|aYOgRZN{[Xl? NHHDSVQ2dU1? M4HyVVJp MVnEUXNQ MnfDbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNkW2NUc,OjV5MU[1OlE9N2F-
95D NGHlc2JCeG:ydH;zbZMhSXO|YYm= Mn7aOY1O NF\YbY0zcA>? MW\EUXNQ M135UolvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNkW2NUc,OjV5MU[1OlE9N2F-
A549  NEn3cItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;CcVNuVQ>? NX:xTWJiOmh? NX6zdHZiTE2VTx?= MV3y[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNkW2NUc,OjV5MU[1OlE9N2F-
95D M3\GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\HOVA{dU1? NGrXZVEzcA>? MnKwSG1UVw>? M{PkPZJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? MoDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MU[1OlEoRjJ3N{G2OVYyRC:jPh?=
Nara-H NUmxUndQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[wOY1O NInRSoQ1QGh? NWHxbZBJ\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> NHPo[Hg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwOVA{Oyd-MkG4NFUxOzN:L3G+
HUVECs MYrGeY5kfGmxbjDBd5NigQ>? MXKxNI1O NHTWU5cxNjWq Mmnm[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= MlPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2Nki1PVIoRjJzNE[4OVkzRC:jPh?=
HepG2 NWDOcWJJSXCxcITvd4l{KEG|c3H5 MX[ycW0> M3Gw[FFp NIO0T4pmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuIHTlZZRp NULHbmplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVM3QTFpPkKxOFU{PjlzPD;hQi=>
U-2 OS MX\xTHRUKGG|c3H5 NXvOemREeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=> NGLTZ2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MoXpdWhVWyCjc4PhfS=> M4Lid5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| M3fDdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY MUXxTHRUKGG|c3H5 Mmn6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 Mm\OdWhVWyCjc4PhfS=> NF22XFByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NHfub4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NYrROI56eUiWUzDhd5NigQ>? NX\0bY5neUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NHe2PIhyUFSVIHHzd4F6 M1PZbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NEOxUpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH M1:ycpFJXFNiYYPzZZk> MlfOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NYTaZ3l[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 M1SyUpFJXFNiYYPzZZk> NGrWVlZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= NHTOTmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M{\WeJFJXFNiYYPzZZk> M4rNfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= M1Pzb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NHPiN5pyUFSVIHHzd4F6 NUDJXWdzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NHLVdIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MVHxTHRUKGG|c3H5 MnfJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= M164ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 MYPxTHRUKGG|c3H5 Mn7PdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NX;QZohnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 MoHTdWhVWyCjc4PhfS=> NIP6R5ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= NYK1cIYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 M4jYcJFJXFNiYYPzZZk> NH35bHZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NXXFSZJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NFfzdnRyUFSVIHHzd4F6 NXniUmdbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MoD0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NEfWZWNyUFSVIHHzd4F6 MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NGnVcWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 MYjxTHRUKGG|c3H5 MlPBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 M3fPdJFJXFNiYYPzZZk> M1\QWZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy| MkHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5
CAS No. 5142-23-4
Storage 3 years -20°C powder
Synonyms NSC 66389
Smiles CN1C=NC(=N)C2=C1N=CN2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

selleck catalog

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147) New

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317 New

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

  • Wortmannin

    Wortmannin (KY 12420, SL-2052) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

  • Dactolisib (BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

  • Buparlisib (BKM120)

    Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID